Clinical Trial Update: A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0425 Administered With and Without Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the safety, tolerability, and pharmacokinetics of GDC-0425 with and without gemcitabine in patients with refractory solid tumors or lym…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Solid Tumors

Drugs mentioned

• GDC-0425
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: Genentech, Inc. | Conditions: Solid Tumor | Phase 1 | Status: COMPLETED